Bristol-Myers Squibb Company (BMY) Shares Sold by Suntrust Banks Inc.

Bristol-Myers Squibb Company (BMY) Shares Sold by Suntrust Banks Inc.

Suntrust Banks Inc. cut its position in Bristol-Myers Squibb Company (NYSE:BMY) by 0.9% during the third quarter, Holdings Channel reports. The institutional investor owned 816,359 shares of the biopharmaceutical company’s stock after selling 7,052 shares during the period. Suntrust Banks Inc.’s holdings in Bristol-Myers Squibb Company were worth $44,016,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Banced Corp raised its stake in shares of Bristol-Myers Squibb Company by 41.0% in the second quarter. Banced Corp now owns 5,884 shares of the biopharmaceutical company’s stock worth $348,000 after buying an additional 1,710 shares in the last quarter. Botty Investors LLC increased its position in Bristol-Myers Squibb Company by 3.1% in the second quarter. Botty Investors LLC now owns 83,520 shares of the biopharmaceutical company’s stock worth $6,143,000 after buying an additional 2,500 shares during the last quarter. Robeco Institutional Asset Management B.V. increased its position in Bristol-Myers Squibb Company by 49.5% in the second quarter. Robeco Institutional Asset Management B.V. now owns 703,768 shares of the biopharmaceutical company’s stock worth $51,761,000 after buying an additional 233,106 shares during the last quarter. YHB Investment Advisors Inc. increased its position in Bristol-Myers Squibb Company by 8.7% in the second quarter. YHB Investment Advisors Inc. now owns 60,008 shares of the biopharmaceutical company’s stock worth $4,414,000 after buying an additional 4,805 shares during the last quarter. Finally, Oakbrook Investments LLC increased its position in Bristol-Myers Squibb Company by 19.5% in the second quarter. Oakbrook Investments LLC now owns 30,604 shares of the biopharmaceutical company’s stock worth $2,251,000 after buying an additional 5,000 shares during the last quarter. Hedge funds and other institutional investors own 69.90% of the company’s stock.

Shares of Bristol-Myers Squibb Company (NYSE:BMY) traded up 1.96% during mid-day trading on Friday, hitting $47.74. 22,918,662 shares of the stock were exchanged. The stock has a market cap of $79.78 billion, a price-to-earnings ratio of 18.02 and a beta of 0.94. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $77.12. The company has a 50-day moving average price of $56.53 and a 200-day moving average price of $58.25.

Bristol-Myers Squibb Company (NYSE:BMY) last announced its earnings results on Thursday, January 26th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.67 by $0.04. Bristol-Myers Squibb Company had a net margin of 22.94% and a return on equity of 31.39%. The business had revenue of $5.24 billion for the quarter, compared to analysts’ expectations of $5.14 billion. During the same quarter last year, the business earned $0.38 EPS. The company’s quarterly revenue was up 22.3% on a year-over-year basis. Equities analysts expect that Bristol-Myers Squibb Company will post $2.94 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 1st. Stockholders of record on Friday, January 6th will be given a dividend of $0.39 per share. This is a positive change from Bristol-Myers Squibb Company’s previous quarterly dividend of $0.38. The ex-dividend date is Wednesday, January 4th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.27%. Bristol-Myers Squibb Company’s dividend payout ratio (DPR) is 58.87%.

A number of equities analysts recently issued reports on the stock. Deutsche Bank AG set a $42.00 price objective on shares of Bristol-Myers Squibb Company and gave the stock a “hold” rating in a report on Friday. Jefferies Group LLC dropped their price objective on shares of Bristol-Myers Squibb Company to $60.00 in a report on Friday. Zacks Investment Research raised shares of Bristol-Myers Squibb Company from a “sell” rating to a “hold” rating in a report on Tuesday, January 24th. Barclays PLC dropped their price objective on shares of Bristol-Myers Squibb Company from $65.00 to $58.00 and set an “equal weight” rating on the stock in a report on Tuesday, January 24th. Finally, BMO Capital Markets raised their price objective on shares of Bristol-Myers Squibb Company from $47.00 to $53.00 and gave the stock a “market perform” rating in a report on Monday, January 23rd. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $63.44.

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Related posts

Leave a Comment